Showing results 1 to 1 of 1
| Issue Date | Title | Journal Title |
|---|---|---|
| 2025 | LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy | JOURNAL OF THORACIC ONCOLOGY |